Compare Match Group Inc (MTCH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Neurocrine Biosciences Inc — how do they compare? Match Group Inc trades at $41.64 (market cap $9.53B), while Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Match Group Inc pays a 1.93% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MTCH | NBIX | |
|---|---|---|
Market Cap | $9.53B | $14.36B |
Volume | 3,228,794 | 1,237,180 |
Sector | Media | Health |
52-Week High | $44.40 | $185.50 |
52-Week Low | $28.90 | $123.10 |
Typical Hold Time | 115 Days | 23 Days |
Enterprise Value | $12.49B | $14.37B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $40.86, up 0.59% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a P/E of 14.71, net income margin of 20.17%, and consistent cash flow generation. Recent earnings beat expectations in Q2 2026, and positive news highlights product innovation and growth in Hinge.
The outlook is positive, supported by margin expansion and strategic initiatives, but risks include high debt levels and competitive pressures. Wall Street sentiment is bullish with a $42.29 price target, offering modest upside from current levels.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
